Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Escherichia coli | fused N-acetyl glucosamine-1-phosphate uridyltransferase/glucosamine-1-phosphate acetyl transferase | Starlite/ChEMBL | References |
Homo sapiens | aurora kinase B | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | mitogen-activated protein kinase 5 | aurora kinase B | 303 aa | 299 aa | 22.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | AGC family protein kinase | 0.0068 | 0 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0068 | 0 | 0.5 |
Echinococcus granulosus | aurora kinase A | 0.0068 | 0 | 0.5 |
Entamoeba histolytica | protein kinase , putative | 0.0068 | 0 | 0.5 |
Loa Loa (eye worm) | AUR protein kinase | 0.0068 | 0 | 0.5 |
Entamoeba histolytica | serine/threonine- protein kinase 6 , putative | 0.0068 | 0 | 0.5 |
Trichomonas vaginalis | AGC family protein kinase | 0.0068 | 0 | 0.5 |
Entamoeba histolytica | protein kinase, putative | 0.0068 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | N-acetylglucosamine-1-phosphate uridyltransferase | 0.0684 | 1 | 0.5 |
Mycobacterium ulcerans | bifunctional N-acetylglucosamine-1-phosphate uridyltransferase/glucosamine-1-phosphate acetyltransferase | 0.0684 | 1 | 1 |
Schistosoma mansoni | protein kinase | 0.0068 | 0 | 0.5 |
Brugia malayi | serine/threonine kinase 12 | 0.0068 | 0 | 0.5 |
Trichomonas vaginalis | AGC family protein kinase | 0.0068 | 0 | 0.5 |
Echinococcus multilocularis | aurora kinase A | 0.0068 | 0 | 0.5 |
Trypanosoma cruzi | aurora B kinase, putative | 0.0068 | 0 | 0.5 |
Brugia malayi | serine/threonine protein kinase 6 | 0.0068 | 0 | 0.5 |
Loa Loa (eye worm) | AUR protein kinase | 0.0068 | 0 | 0.5 |
Trichomonas vaginalis | AGC family protein kinase | 0.0068 | 0 | 0.5 |
Trypanosoma brucei | aurora B kinase | 0.0068 | 0 | 0.5 |
Plasmodium vivax | serine/threonine protein kinase 6, putative | 0.0068 | 0 | 0.5 |
Entamoeba histolytica | protein kinase domain containing protein | 0.0068 | 0 | 0.5 |
Treponema pallidum | licC protein (licC) | 0.0125 | 0.0931 | 0.5 |
Mycobacterium tuberculosis | Probable UDP-N-acetylglucosamine pyrophosphorylase GlmU | 0.0684 | 1 | 1 |
Entamoeba histolytica | protein kinase, putative | 0.0068 | 0 | 0.5 |
Giardia lamblia | Aurora kinase | 0.0068 | 0 | 0.5 |
Entamoeba histolytica | serine/threonine protein kinase 6, putative | 0.0068 | 0 | 0.5 |
Brugia malayi | serine/threonine-protein kinase 6 | 0.0068 | 0 | 0.5 |
Loa Loa (eye worm) | AUR protein kinase | 0.0068 | 0 | 0.5 |
Entamoeba histolytica | serine/threonine- protein kinase 6, putative | 0.0068 | 0 | 0.5 |
Echinococcus multilocularis | serine:threonine protein kinase 12 B | 0.0068 | 0 | 0.5 |
Plasmodium falciparum | serine/threonine protein kinase, putative | 0.0068 | 0 | 0.5 |
Echinococcus granulosus | serine:threonine protein kinase 12 B | 0.0068 | 0 | 0.5 |
Leishmania major | protein kinase, putative | 0.0068 | 0 | 0.5 |
Toxoplasma gondii | eukaryotic initiation factor-2B, gamma subunit, putative | 0.0125 | 0.0931 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.97 uM | Inhibition of Escherichia coli ATCC 27325 GlmU expressed in Escherichia coli HMS174(DE3) incubated for 15 mins prior to MgCl2 addition measured after 30 mins by malachite green staining-based assay | ChEMBL. | 25262942 |
IC50 (binding) | = 18.1 uM | Inhibition of human AURKB incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human IRAK4 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human IRAK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human JAK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human JAK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human JAK3 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human CDK1 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human CDK2 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
IC50 (binding) | > 30 uM | Inhibition of human CDK9 incubated for 20 mins prior to MgCl2 addition measured after 90 mins by mobility shift assay | ChEMBL. | 25262942 |
PB (ADMET) | = 84.1 % | Serum protein binding in human at 10 uM after 30 mins by ultrafiltration method | ChEMBL. | 25262942 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.